Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Ulcerative Colitis Health Center

Font Size

Drug for Colitis, Crohn's Disease Shows Promise

Results of early trials were stronger with colitis patients, however

WebMD News from HealthDay

By Amy Norton

HealthDay Reporter

WEDNESDAY, Aug. 21 (HealthDay News) -- An experimental drug may help some people who have inflammatory bowel disease that has failed to respond to current medications, two new clinical trials find.

The drug, called vedolizumab, is being developed to treat the two main forms of inflammatory bowel disease (IBD) -- ulcerative colitis and Crohn's disease. Both arise when the immune system launches an abnormal attack on the lining of the digestive tract, leading to chronic inflammation and symptoms such as abdominal cramps, diarrhea and rectal bleeding.

In the new trials, reported in the Aug. 22 issue of the New England Journal of Medicine, researchers found that vedolizumab worked in some cases where standard IBD medications had failed.

The drug was more effective for colitis than for Crohn's, however, and an expert not involved in the studies said he suspects vedolizumab might be approved for colitis first.

Overall, the results are "very exciting," said Dr. Fabio Cominelli, chief of gastroenterology and liver disease at Case Western Reserve University School of Medicine, in Cleveland.

"This is a potential new weapon in our armamentarium," said Cominelli, who wrote an editorial that accompanied the reports.

The two studies included more than 2,000 patients with either colitis or Crohn's who had failed to get enough relief from standard medications, which include immune-system suppressors such as corticosteroids, azathioprine (brand name Imuran) and mercaptopurine (Purinethol).

About half of the patients had also tried the most recently developed drugs for IBD, known as anti-TNF agents. Those drugs -- infliximab (Remicade), adalimumab (Humira) and certolizumab (Cimzia) -- are given intravenously, and block an inflammatory protein called tumor necrosis factor (TNF).

In one trial, nearly 900 colitis patients were given two infusions of either vedolizumab or a placebo, two weeks apart. After six weeks, 47 percent of the vedolizumab patients had a "clinical response," or a meaningful drop in their symptoms.

Those patients were then randomly assigned to either stay with the drug -- getting infusions every four weeks or every eight weeks -- or receive placebo infusions.

After a year, 42 percent to 45 percent of the vedolizumab patients were in remission, compared with 16 percent of the placebo group.

Today on WebMD

basket of vegetables
IBD Overview Slideshow
Ulcerative Colitis Managing Flares
what is ibs

Supplements UC
Ulcerative Colitis Health Check
Ulcerative Colitis Diet
Ulcerative Colitis Diet Yogurt

Ulcerative Colitis Surgery
Ulcerative Colitis Medications
Exercising When You Have A GI Disorder
Picture Of The Intestines
Image Collection